Last reviewed · How we verify
Entereg
Entereg is a Small molecule drug developed by Hartford Hospital. It is currently in Phase 2 development for Postoperative ileus.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Entereg |
|---|---|
| Sponsor | Hartford Hospital |
| Target | Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Approved indications
- Postoperative ileus
Common side effects
Key clinical trials
- A Study of Surgical Techniques During Cystectomy (PHASE3)
- Alvimopan as a Rescue Treatment of Postoperative Ileus (PHASE4)
- Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol (PHASE3)
- Alvimopan as Rescue in Post op Ileus (PHASE3)
- Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC (PHASE2)
- Trial of Alvimopan in Major Spine Surgery (PHASE4)
- Conventional VS Enhanced Recovery After Surgery Protocols in Emergency GIT Surgery
- Alvimopan Use in Polytraumatized Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Entereg CI brief — competitive landscape report
- Entereg updates RSS · CI watch RSS
- Hartford Hospital portfolio CI
Frequently asked questions about Entereg
What is Entereg?
What is Entereg used for?
Who makes Entereg?
What development phase is Entereg in?
What does Entereg target?
Related
- Target: All drugs targeting Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
- Manufacturer: Hartford Hospital — full pipeline
- Therapeutic area: All drugs in Pain
- Indication: Drugs for Postoperative ileus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing